Xtandi

DRUG3 trials

Sponsors

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Bayer, Cancer Trials Ireland

Conditions

Bone MetastasesCarcinoma ProstateCastration-resistant Prostate CancerMetastatic CancerProstatic Neoplasms, Castration-Resistant

Phase 2

A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.

CompletedNCT03103724

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoCarcinoma Prostate

Start: 2017-03-16End: 2021-04-23Updated: 2021-04-26

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

TerminatedNCT03869762

Cancer Trials IrelandBone Metastases, Castration-resistant Prostate Cancer, Metastatic Cancer

Start: 2019-01-09End: 2019-01-12Updated: 2024-09-25

Unknown Phase

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

WithdrawnNCT03325127

BayerProstatic Neoplasms, Castration-Resistant

Start: 2017-10-30End: 2018-09-28Updated: 2018-10-31

Related Papers

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

Therapeutic Advances in Medical Oncology2024-01-014 citations

A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

Journal of Clinical Oncology2021-05-201 citations